Minimal residual disease (MRD) after induction and/or consolidation chemotherapy is a significant risk factor for relapse in patients with acute myeloid leukemia (AML), authors noted in a recent review. They summarized methodologies employed in AML MRD detection and their application in clinical studies that provide evidence supporting the clinical utility of AML MRD testing. They also pointed out that future MRD evaluations will likely require combining multi-parameter flow cytometry and high-sensitivity molecular techniques performed during and after treatment in order to fully assess response.
Zhou Y, Wood B. Methods of detection of measurable residual disease in AML. [Published online ahead of print November 2, 2017]. Curr Hematol Malig Rep. doi:10.1007/s11899-017-0419-5.
This Week's Must Reads
Must Reads in AML
Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al
Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al
Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al
Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al
Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al